- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01990274
The Utility of Intensified Case Finding Combined With a Package of Novel TB Diagnostics Using a Mobile Clinic in Africa (XACT)
The Utility of Intensified Case Finding Combined With a Package of Novel TB Diagnostics Using a Mobile Clinic in Africa- a Randomized Controlled Trial (XACT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Despite recent advances in diagnosis and the availability of effective anti-tuberculous treatment TB remains one of the world's most devastating infectious disease, with a global prevalence of more than 14 million in 2006. In high burden communities with the co-localised HIV epidemic, a major problem hampering control efforts and promulgating the TB epidemic is the large reservoir of undiagnosed TB disease. This comprises over 50% of the total TB burden. HIV-infection with its atypical yet infectious presentation where immunity is attenuated worsens this undetected reservoir. Thus, there is a large case load in the community that do not access health care or do so late in the course of the disease and there is thus ongoing disease transmission within the community. If this caseload in not addressed then the TB epidemic will never be controlled.
Intensified case finding seeks to address this problem. Intensified case finding is a strategy to identify and treat people with TB who have not sought diagnostic services on their own initiative. By contrast, passive case finding is only able to identify people with TB presenting to health care facilities. In 2008 the WHO and Stop TB partnership identified intensified case-finding as one of four core TB prevention strategies necessary to meet the sixth Millennium Development Goal of halving the prevalence of TB by 2015. To date, a number of studies have illustrated the success of intensified case finding to increase case-detection rates (especially in HIV-infected populations) and to shorten time to diagnosis thereby limiting attendant morbidity and mortality.
Given both the importance and resource-intensive nature of intensified case finding it is essential that the optimal, operationally feasible and most cost-effective screening strategy be used. To date, screening strategies have varied widely across studies but all have used a combination of symptom screening, radiological (CXR) and microscopy-centre based laboratory diagnostics (smear microscopy and, if available and cost permitting, TB culture). This is a major shortcoming as it is now well established that these standard diagnostic tools perform sub-optimally especially in high HIV prevalent settings. With the recent development of a number of novel TB diagnostic tools with superior performance compared to conventional modalities, and the potential for point-of-care (POC) and point-of-treatment usage, it is imperative that intensified case-finding strategies be reviewed. The 2010 updated WHO "Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings" recommends the use of a clinical algorithm for intensified case finding programmes for adults and adolescents living with HIV and it is important that the incremental diagnostic benefit together with the feasibility and cost-effectiveness of these novel TB diagnostic tools be assessed for use in intensified case finding programmes within the context of these updated guidelines.
In 2009, Cepheid released the Xpert® MTB/RIF Assay, which is the only system able to deliver answers directly from unprocessed samples by combining on-board preparation of the sample with real-time PCR in less than 2 hours. Additionally, the Xpert® MTB/RIF Assay allows for simultaneous on-demand molecular testing for the detection of M.tb and RIF resistance. The GeneXpert™ system consists of a GeneXpert instrument, personal computer and disposable fluidic cartridges. The system combines cartridge-based sample preparation with amplification and detection in a fully integrated and automated nucleic acid analysis instrument. GeneXpert has been shown to be an accurate tool for the rapid diagnosis of tuberculosis in both smear-positive and smear-negative samples (with a single Xpert test having a sensitivity of ~ 70% in smear-negative samples. A large demonstration study of Gene Xpert based at microscopy-centres is currently underway and preliminary data appear promising. However, GeneXpert technology has not been used as part of a screening strategy for intensified case finding and its operational feasible as a point-of-treatment diagnostic technology based in a mobile clinic has not yet been assessed.
In our recent review we have proposed urinary LAM as a useful "rule in" test for TB in HIV-infected subjects with advanced immune-suppression. Additionally, the recent development of a point-of-care urine LAM lateral flow strip test - the Determine TB® - with preliminary results suggesting equivalent performance to the LAM ELISA make it an appealing diagnostic for high HIV prevalence areas. A recent study has shown urine LAM to be more sensitive than smear-microscopy in an ARV clinic-based TB screening study. The use of the Determine TB® lateral flow strip test has not been studied as part of an intensified case finding strategy for population-based surveys. The Determine TB® lateral flow test will be used for screening of HIV-infected patients at point-of-care within the community and subsequent TB clinic referral for sputum-based diagnostics.
The XACT study has a randomised control study design to evaluate the impact of a package of novel TB diagnostic tools in the community using a mobile unit compared to standard intensive-case finding methods. The feasibility of performing new TB diagnostics at the point-of-care will be examined to determine if the proportion of patients identified, initiating, and completing TB treatment, is greater compared to the standard diagnostic arm. Further, the cost-effectiveness of TB cases detected and successfully completing treatment between study arms can also be investigated.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Sassari, Italy, 07100
- University of Sassari
-
-
-
-
-
Nijmegen, Netherlands, 6500 HB
- Radboud University
-
-
-
-
Western Province
-
Cape Town, Western Province, South Africa, 7945
- University of Cape Town
-
-
-
-
-
Harare, Zimbabwe, P O Box A178 Avondale
- University of Zimbabwe
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Community participant willing to complete community-based symptom screening, urine testing and/or undergo TB diagnostic tests at the local TB clinic.
- Provision of informed consent.
HIV-negative adults (older than 18 years) with 1 or more of the following:
- cough ≥ 2 weeks
- loss of weight
- persistent fever ≥ 2 weeks and/or
- a single recorded temp > 38°C
- night sweats
- generalized fatigue
- hemoptysis or
- chest pain
- Any HIV+ve adult (older than 18 years).
Exclusion Criteria:
- Inability to provide informed consent (e.g. mentally impaired).
- Patients self-presenting to the TB clinics.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Novel
Patients in this arm will receive 3 sputum samples for GeneXpert MTB/RIF assay and MGIT liquid TB culture.
|
Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
Automated nucleic-acid amplification test (fully integrated) test for TB
Other Names:
|
ACTIVE_COMPARATOR: Standard
Patients in this arm will receive 2 sputum samples for fluorescence smear microscopy and MGIT liquid TB culture.
|
Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of novel intensive-case finding diagnostic tools to standard intensive-case finding strategy
Time Frame: 2 months
|
The proportion of culture-positive TB cases initiating TB treatment in each study arm.
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of culture-positive TB cases completing TB treatment in each study arm
Time Frame: 6 months
|
The number of patients that are enrolled, randomized to a study arm, diagnosed with TB, and completing TB treatment.
|
6 months
|
Feasibility of performing Xpert MTB/RIF at the point-of-care in a mobile unit using an alternative power supply
Time Frame: 6 months
|
Feasibility indicators for the performance of Xpert in a mobile unit.
These include turn-around-time, user appraisal and assessments and performance comparisons between mobile clinic and laboratory-based Xpert MTB/RIF.
|
6 months
|
Cost per TB case detected between study arms
Time Frame: 6 months
|
Documentation of patient costs for TB diagnosis.
|
6 months
|
Cost per TB case successfully completing treatment between study arms
Time Frame: 6 months
|
Documentation of patient costs for completing TB treatment.
|
6 months
|
Determining whether LAM is present at sub-ELISA concentrations using mass spectroscopy of urine samples from TB patients
Time Frame: 6 months
|
Urine from subjects will be used to verify whether LAM is present in the urine of HIV-infected persons with TB at sub-ELISA concentrations using mass spectrometry.
LAM standards will be used in spiked urine samples to evaluate limit of detection and specificity.
|
6 months
|
Validating the electronic chest X-ray scoring system for Computer Aided Diagnostics (CAD) of TB
Time Frame: 6 months
|
The method employs an automatic scoring algorithm to interpret digitalized chest x-rays.
The system is suited to x-rays being done in remote areas where medical expertise is not available.
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Keertan Dheda, MBChB, PhD, University of Cape Town
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- XACT.2011.10800.003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
National Institute of Allergy and Infectious Diseases...CompletedPulmonary Tuberculosis | Multidrug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisKorea, Republic of
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... and other collaboratorsActive, not recruitingTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TBSouth Africa
Clinical Trials on Smear microscopy
-
University of Cape TownNational Institutes of Health (NIH); University of Cape Town Lung Institute; Medical...Completed
-
Ataulpho de Paiva FoundationBill and Melinda Gates FoundationCompleted
-
University of Cape TownRadboud University Medical Center; McGill University; University of Cape Town... and other collaboratorsCompletedTuberculosisZimbabwe, South Africa, Zambia
-
University of WashingtonMinnesota Ovarian Cancer AllianceTerminatedStage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IVA Ovarian Cancer AJCC v8 | Stage IVB Ovarian... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingEndometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Serous Adenocarcinoma | Malignant Uterine Neoplasm | Endometrial Mucinous Adenocarcinoma | Uterine Corpus CarcinosarcomaUnited States
-
University Hospital, ToulouseRecruiting
-
Istanbul Medeniyet UniversityActive, not recruiting
-
Johns Hopkins UniversityAmerican Society for Gastrointestinal Endoscopy; Pentax Medical CorporationCompletedBarrett's Esophagus, Esophageal Intraepithelial NeoplasiaUnited States, Germany
-
University of Cape TownCompletedTuberculosisSouth Africa
-
Yale UniversityCompletedAtopic DermatitisUnited States